Internal Medicine, Endocrinology, Diabetes, & Metabolism · Idaho Falls, ID
NPI
1932109931
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3910 Washington Parkway
Idaho Falls, ID, 83404
Phone (208) 523-1122
Groups this clinician bills Medicare through
Medicare paid, 2024
$171K
15,520 services
Medicare patients, 2024
844
Average age 73
Drug cost, 2024
$5.0M
23,200 prescriptions
Company payments, 2025
$1,126
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Liljenquist was code 36415 (venipuncture blood collection), 992 times for 624 patients. In total David R Liljenquist billed 15,520 services in 121 codes, and Medicare paid $171K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 992 | 624 | $8.59 | $8,522 |
| 99214 Office E&M - Established | Office | 832 | 597 | $79.60 | $66K |
| 83036 Blood Count | Office | 547 | 392 | $9.48 | $5,184 |
| 83970 Clinical Chemistry | Office | 371 | 284 | $40.17 | $15K |
| 84443 Clinical Chemistry | Office | 339 | 262 | $16.30 | $5,527 |
| 80069 Clinical Chemistry | Office | 303 | 245 | $8.46 | $2,563 |
| 80061 Clinical Chemistry | Office | 272 | 255 | $13.04 | $3,547 |
| 82306 Clinical Chemistry | Office | 248 | 207 | $28.62 | $7,098 |
| 84439 Clinical Chemistry | Office | 241 | 192 | $8.78 | $2,116 |
| 84481 Clinical Chemistry | Office | 240 | 192 | $16.49 | $3,957 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 206 | 199 | $12.26 | $2,525 |
| 82310 Clinical Chemistry | Office | 200 | 152 | $5.02 | $1,004 |
| 99204 Office E&M - New | Office | 152 | 152 | $108.17 | $16K |
| 82570 Clinical Chemistry | Office | 150 | 147 | $5.02 | $754 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 150 | 30 | $4.32 | $647 |
By year: 2022 $226K for 24,662 services; 2023 $303K for 32,008 services; 2024 $171K for 15,520 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 992 | 624 | $8.59 | $8,522 |
| 83036 Blood Count | 547 | 392 | $9.48 | $5,184 |
| 83970 Clinical Chemistry | 371 | 284 | $40.17 | $15K |
| 84443 Clinical Chemistry | 339 | 262 | $16.30 | $5,527 |
| 80069 Clinical Chemistry | 303 | 245 | $8.46 | $2,563 |
| 80061 Clinical Chemistry | 272 | 255 | $13.04 | $3,547 |
| 82306 Clinical Chemistry | 248 | 207 | $28.62 | $7,098 |
| 84439 Clinical Chemistry | 241 | 192 | $8.78 | $2,116 |
| 84481 Clinical Chemistry | 240 | 192 | $16.49 | $3,957 |
| 82310 Clinical Chemistry | 200 | 152 | $5.02 | $1,004 |
Medicare prescription drug claims, 2024
In 2024, the drug David R Liljenquist prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,808 prescriptions and refills. In total David R Liljenquist wrote 23,200 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,808 | 4,471 | 451 | $20K |
| Metformin Hcl Er Metformin Hcl | 1,407 | 3,538 | 389 | $13K |
| Atorvastatin Calcium Generic | 1,000 | 2,469 | 257 | $9,382 |
| Rosuvastatin Calcium Generic | 772 | 1,898 | 214 | $8,446 |
| Ozempic Semaglutide | 695 | 890 | 147 | $815K |
| Losartan Potassium Generic | 694 | 1,865 | 201 | $4,739 |
| Mounjaro Tirzepatide | 653 | 720 | 135 | $739K |
| Omeprazole Generic | 546 | 1,281 | 146 | $5,836 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 524 | 1,025 | 154 | $80K |
| Pioglitazone Hcl Generic | 481 | 1,169 | 118 | $4,699 |
| Simvastatin Generic | 435 | 1,133 | 106 | $2,206 |
| Ezetimibe Generic | 422 | 986 | 101 | $8,598 |
| Glimepiride Generic | 414 | 1,030 | 117 | $2,970 |
| Lisinopril Generic | 386 | 972 | 102 | $2,686 |
| Metformin Hcl Generic | 364 | 874 | 97 | $2,290 |
Brand drugs: 6,327 claims; generic drugs: 16,216 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David R Liljenquist $1,126 ($1,126 in general payments such as food, travel and fees) from 28 companies. The largest payer was Abbott Laboratories with $130.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 6 | $130 |
| Chiesi USA, Inc. | 3 | $105 |
| Madrigal Pharmaceuticals MDGL | 5 | $86.24 |
| Xeris Pharmaceuticals, Inc. | 4 | $78.4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70.14 |
| Lilly USA, LLC LLY | 4 | $61.04 |
| Corcept Therapeutics CORT | 3 | $57.76 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $51.07 |
| Amgen Inc. AMGN | 3 | $49.74 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $49.22 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.